Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM.

Oncotarget. 2013 May;4(5):691-704.

PMID:
23674566
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.

PMID:
23152004
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource, Tilley WD, Butler LM.

Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9.

PMID:
22573351
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Hsp90 as a therapeutic target in prostate cancer.

Solit DB, Scher HI, Rosen N.

Semin Oncol. 2003 Oct;30(5):709-16. Review.

PMID:
14571418
[PubMed - indexed for MEDLINE]
6.

Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Chan SC, Li Y, Dehm SM.

J Biol Chem. 2012 Jun 1;287(23):19736-49. doi: 10.1074/jbc.M112.352930. Epub 2012 Apr 24.

PMID:
22532567
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

O'Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, Wang Z.

Prostate. 2012 Jul 1;72(10):1117-23. doi: 10.1002/pros.22458. Epub 2011 Dec 7.

PMID:
22161776
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, M√ľnster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.

Clin Cancer Res. 2002 May;8(5):986-93.

PMID:
12006510
[PubMed - indexed for MEDLINE]
Free Article
9.

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C.

Endocr Relat Cancer. 2013 May 21;20(3):321-37. doi: 10.1530/ERC-12-0240. Print 2013 Jun.

PMID:
23507703
[PubMed - indexed for MEDLINE]
Free Article
10.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

PMID:
23023561
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT.

Cancer Biol Ther. 2013 Apr;14(4):347-56. doi: 10.4161/cbt.23626. Epub 2013 Jan 28.

PMID:
23358469
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.

Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916.

PMID:
21349995
[PubMed - indexed for MEDLINE]
Free Article
13.

AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S.

Neoplasia. 2013 Sep;15(9):1009-17.

PMID:
24027426
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.

Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z.

Mol Endocrinol. 2009 Dec;23(12):1963-72. doi: 10.1210/me.2009-0188. Epub 2009 Oct 23.

PMID:
19855091
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Shafi AA, Cox MB, Weigel NL.

Steroids. 2013 Jun;78(6):548-54. doi: 10.1016/j.steroids.2012.12.013. Epub 2013 Feb 1.

PMID:
23380368
[PubMed - in process]
Free PMC Article
16.

Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.

McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA.

Cancer Res. 2013 Aug 15;73(16):5066-79. doi: 10.1158/0008-5472.CAN-12-4520. Epub 2013 Jun 25.

PMID:
23801747
[PubMed - indexed for MEDLINE]
17.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

PMID:
20823238
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J.

Mol Cancer Ther. 2005 Sep;4(9):1311-9.

PMID:
16170022
[PubMed - indexed for MEDLINE]
Free Article
19.

Berberine suppresses androgen receptor signaling in prostate cancer.

Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H.

Mol Cancer Ther. 2011 Aug;10(8):1346-56. doi: 10.1158/1535-7163.MCT-10-0985. Epub 2011 May 25.

PMID:
21613449
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.

PMID:
23786771
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk